DSM will conduct further cost cutting at its Pharma business as part of a wider ‘profit improvement initiative’ that will see it cut 1,000 jobs over the next 18 months.
DSM’s microbial fermentation CMO business unit and UK-based biopharmaceutical company, PolyTherics, have formed an agreement to develop and manufacture PolyTherics’ lead ‘biobetter’ product, HiPEG IFN a-2a.
DSM has confirmed that three workers were killed at the weekend after an industrial accident at its food and pharmaceutical ingredient plant in southern Italy.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
Dutch chemicals giant DSM and France’s LibraGen are targeting the chemical and pharmaceutical industries with their new chiral amine production accord, which aims to develop a range of new catalytic enzymes.
Dutch chemical group DSM has acquired Polymer Technology Group
(PTG) and predicted its best financial year to date following
organic sales growth of 14 per cent for the first quarter.
Netherlands-based DSM has invested an undisclosed sum in Danish
purification technology company Upfront Chromatography to boost its
protein separation business.
Dutch ingredients firm DSM has announced plans to carve out its
anti-infectives business and boost its presence in Asian markets
following a review of the active ingredient unit.
DSM Venturing, the investment arm of the Dutch chemical giant, has
announced it has snapped a 10 per cent share in pharma materials
provider Micromuscle.
A year after it published its five-year strategy: Vision 2010 -
Building on Strengths - DSM's commitment is showing no sign of
slowing as is continues to invest in the expansion of its
pharmaceutical production capabilities around...
Chemicals and nutrition group DSM has reported strong profits for
the first quarter in 2006, including in its pharma business, as
higher prices and lower costs have helped it overcome the increase
in raw material costs.
Rising prices globally have helped Dutch chemicals manufacturer DSM
go back to profit in Q4, up to €112m (€134m) from €3m in the red a
year ago, with operating profits in its Life Science division
almost doubling to €39m, albeit thanks...
A restructure of DSM's pharma businesses will see the closure of
its Pharma Chemicals site in Michigan, US, in the first half of
2007 and the mothballing of the DSM Biologics facilities in
Montreal, Canada at the beginning of...
DSM is expanding its anti-infectives production facilities in
India, as part of a global restructuring program to improve
profitability and retain DSM's position in the penicillin market.
DSM announced that higher margins and lower fixed costs had boosted
operating profits by 44 per cent to €220 million in the third
quarter, with the performance materials and industrial chemicals
divisions leading the increase.
Dutch group DSM, one of Europe's top three ingredient suppliers to
drug makers, increased sales of pharma products during the second
quarter but continued losses from the antibiotics market halved the
Life Sciences operating...
DSM Anti-Infectives, the world's largest producer of antibiotics,
is planning to expand a manufacturing plant for a key intermediate
used in the manufacture of cephalosporins that will make it the
largest producer of the compound...
DSM has said it expects 'clearly higher' net profit from ordinary
operations in 2004, after reporting an unexpected increase in
first-quarter operating earnings.
DSM will cut around 500 jobs at its Chemelot site in Geleen, the
Netherlands over the next two years, in an effort to cut costs by
over €50 million per annum. The jobs will largely go in support
services and manufacturing staff departments.
DSM of the Netherlands saw its operating profit slump 23 per cent
to €294 million last year, hit by higher raw material costs and
declining sales of its life sciences products.
DSM reports a disappointing set of second quarter results and says
it is unlikely to meet its 2002 operating profit level this year;
the group blames weaker demand for its products and negative
currency factors. Restructuring drive...
DSM has taken a 25 per cent interest in Nijmegen, Netherlands-based
Chiralix in move which both expands DSM's capabilities in
early-stage drug development and Chiralix' position in
stereochemistry
The proposed sale of Roche vitamins to Dutch firm DSM is to go
through second phase merger investigations by the European
Commission due to competition concerns in the feed enzymes market.
Dutch life sciences company DSM has broken ground on a new site in
Montreal, Canada, set to become a large-scale biopharmaceuticals
plant. Phase one - at a cost of €100m - due for completion by 2005.
The global economic downturn marked 2003 first quarter results for
Dutch based life science company DSM but strong autonomous volume
growth boosted figures to higher than 2002.
Dutch life science company DSM reported this week that on Tuesday
three people were killed following an explosion at its Melamine
Plant 2 in Geleen, the Netherlands.
In the second news of the day on a European life science company,
DSM announced this week that from now on it will supply
technologies and services for the initial development phases of new
medicines - supplementing its existing service...
